Click here to return to the Reference Table

Category: Musculoskeletal sarcomas
Cancer type: Osteosarcoma
Descriptor: Therapeutic Development

Reference Number: 411
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-7 (2006)
PubMed link      E-mail link

Reference Number: 1112
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther. 11, 1223-32 (2011)
PubMed link      E-mail link

Reference Number: 1127
Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O'Keefe RJ, Rosier RN. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res. 26, 1283-94 (2011)
PubMed link      E-mail link

Reference Number: 1231
Wang K, Zhuang Y, Liu C, Li Y. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch Biochem Biophys. 526, 38-43 (2012)
PubMed link      E-mail link